Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
AstraZeneca
Express Scripts
Medtronic
Dow

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

KAPSPARGO SPRINKLE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Kapspargo Sprinkle, and when can generic versions of Kapspargo Sprinkle launch?

Kapspargo Sprinkle is a drug marketed by Spil and is included in one NDA. There are two patents protecting this drug.

This drug has seven patent family members in seven countries.

The generic ingredient in KAPSPARGO SPRINKLE is metoprolol succinate. There are sixty drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the metoprolol succinate profile page.

US ANDA Litigation and Generic Entry Outlook for Kapspargo Sprinkle

  Start Trial

A generic version of KAPSPARGO SPRINKLE was approved as metoprolol succinate by ACTAVIS LABS FL INC on January 17th, 2020.

Summary for KAPSPARGO SPRINKLE
Drug patent expirations by year for KAPSPARGO SPRINKLE
Drug Prices for KAPSPARGO SPRINKLE

See drug prices for KAPSPARGO SPRINKLE

Pharmacology for KAPSPARGO SPRINKLE

US Patents and Regulatory Information for KAPSPARGO SPRINKLE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Spil KAPSPARGO SPRINKLE metoprolol succinate CAPSULE, EXTENDED RELEASE;ORAL 210428-001 Jan 26, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Spil KAPSPARGO SPRINKLE metoprolol succinate CAPSULE, EXTENDED RELEASE;ORAL 210428-004 Jan 26, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Spil KAPSPARGO SPRINKLE metoprolol succinate CAPSULE, EXTENDED RELEASE;ORAL 210428-002 Jan 26, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Spil KAPSPARGO SPRINKLE metoprolol succinate CAPSULE, EXTENDED RELEASE;ORAL 210428-004 Jan 26, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Spil KAPSPARGO SPRINKLE metoprolol succinate CAPSULE, EXTENDED RELEASE;ORAL 210428-001 Jan 26, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Spil KAPSPARGO SPRINKLE metoprolol succinate CAPSULE, EXTENDED RELEASE;ORAL 210428-002 Jan 26, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Spil KAPSPARGO SPRINKLE metoprolol succinate CAPSULE, EXTENDED RELEASE;ORAL 210428-003 Jan 26, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Harvard Business School
Moodys
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.